EUON Publishes Nanopinion on Urinary MicroRNA-based Early Cancer Detection Using Nanowire-based Devices

Bergeson & Campbell, P.C.
Contact

Bergeson & Campbell, P.C.

On May 31, 2022, the European Union (EU) Observatory for Nanomaterials (EUON) published a Nanopinion entitled “Urinary MicroRNA-based Early Cancer Detection Using Nanowire-based Devices” by Dr. Yasui Takao on using nanowire devices to extract microRNAs (miRNA) from urine to distinguish cancer patients from healthy individuals and improve the early detection of cancer. According to Yasui, researchers designed a device equipped with 100 million zinc oxide nanowires that can extract a significantly greater variety and quantity of miRNAs from only a milliliter of urine compared to conventional methods. Using the device, they revealed that miRNAs in urine could be a promising biomarker to diagnose brain tumors, finding that many miRNAs derived from brain tumors exist in urine in a stable condition. Yasui states that the results showed that the model can distinguish the patients from non-cancer individuals at a sensitivity of 100 percent and a specificity of 97 percent, regardless of the malignancy and size of tumors.

[View source.]

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Bergeson & Campbell, P.C. | Attorney Advertising

Written by:

Bergeson & Campbell, P.C.
Contact
more
less

Bergeson & Campbell, P.C. on:

Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
- hide
- hide

This website uses cookies to improve user experience, track anonymous site usage, store authorization tokens and permit sharing on social media networks. By continuing to browse this website you accept the use of cookies. Click here to read more about how we use cookies.